Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data

…, H Suzuki, N Shimada, K Chiba, T Ishizaki… - Pharmacology & …, 1997 - Elsevier
As a new approach to predicting in vivo drug metabolism in humans, scaling of in vivo
metabolic clearance from in vitro data obtained using human liver microsomes or hepatocytes is …

Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer

…, T Kawasaki, H Hanai, T Kubota, T Ishizaki… - Annals of internal …, 1998 - acpjournals.org
Background: Omeprazole is metabolized by S-mephenytoin 4′-hydroxylase (CYP2C19) in
the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy …

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies

…, A Nakamura, A Hishida, T Ishizaki - Drug metabolism and …, 2005 - jstage.jst.go.jp
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole,
and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There are genetically …

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and …

JA Goldstein, T Ishizaki, K Chiba… - Pharmacogenetics …, 1997 - journals.lww.com
The 4'-hydroxyIation of S-mephenytoin is polymorphic in man. The poor metabolizer (PM)
phenotype exhibits a lower frequency in Caucasians (2–5%) compared to Oriental populations …

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

…, H Hanai, E Kaneko, T Ishizaki - Clinical …, 1999 - Wiley Online Library
Objective Omeprazole is metabolized by genetically determined S‐mephenytoin 4′‐hydroxylase
(CYP2C19) in the liver. This study aimed to determine whether the effect of …

Genotyping of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population

T Kubota, K Chiba, T Ishizaki - Clinical Pharmacology & …, 1996 - Wiley Online Library
Objective To assess the genotype pattern of S‐mephenytoin 4′‐hydroxylation in an extended
Japanese population. Methods One hundred eighty‐six unrelated, healthy Japanese …

Pharmacokinetics of haloperidol: an update

S Kudo, T Ishizaki - Clinical pharmacokinetics, 1999 - Springer
Haloperidol is commonly used in the therapy of patients with acute and chronic schizophrenia.
The enzymes involved in the biotransformation of haloperidol include cytochrome P450 (…

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

…, H Sugimura, K Ohashi, T Ishizaki… - Clinical …, 2001 - Wiley Online Library
Background Proton pump inhibitors such as omeprazole and lansoprazole are mainly
metabolized by CYP2C19 in the liver. The therapeutic effects of proton pump inhibitors are …

Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance

…, A Stone, ACT Lo, T Kubota, T Ishizaki… - Pharmacogenetics …, 2000 - journals.lww.com
UGT2B7 catalyses the glucuronidation of a diverse range of drugs, environmental chemicals
and endogenous compounds. Hence, coding region polymorphisms of UGT2B7 are …

Evidence that the Degree and Duration of Acid Suppression are Related to Helicobacter pylori Eradication by Triple Therapy

…, C Kodaira, M Nishino, M Ikuma, T Ishizaki… - …, 2007 - Wiley Online Library
Backgrounds and aims: Eradication rates of Helicobacter pylori by a proton pump inhibitor‐based
triple therapy depend on CYP2C19 genotype status. We investigated whether gastric …